Very low doses of rituximab rapidly reduced blood levels of disease-driving B-cells in people with cold agglutinin disease…
Articles by Lindsey Shapiro, PhD
Researchers have developed an artificial intelligence (AI)-based model designed to identify existing medicines that could be repurposed to treat rare…
Nearly 18% of people with autoimmune hemolytic anemia (AIHA), of which cold agglutinin disease (CAD) is one type, were…
Managing the life-threatening consequences of a rare autoimmune condition called ANCA-associated vasculitis (AAV) can be particularly challenging when…
Long-term treatment with Enjaymo (sutimlimab) leads to sustained reductions in red blood cell destruction, anemia, and fatigue, as well…
Distinguishing between primary and secondary cold agglutinin disease (CAD), as well as understanding if cancer is the underlying cause…
Nearly 20% of people with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD), who required blood transfusions…
Treatment with rituximab led to improvements in biomarkers of red blood cell destruction among people with cold agglutinin disease…
A free symposium on complement cascade-targeted treatment approaches for cold agglutinin disease (CAD) will be held live and virtually…
Among people with cold agglutinin disease (CAD), more than half were found to have a related autoimmune disorder called…